Blocking TNF and PD-1 increased the number and activity of tumor-infiltrating CD8+ TIL (31, 47) and enabled to achieve 75% survival versus 20% survival in the case of treatment with anti-PD-1 alone. This evidence concerns the gene CD8A and neoplasm.